# Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

> **NCT02343952** · PHASE2 · COMPLETED · sponsor: **Nasser Hanna, M.D.** · enrollment: 93 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02343952
- **Lead sponsor:** Nasser Hanna, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-09
- **Primary completion:** 2020-08-10
- **Final completion:** 2021-01-01
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2023-09-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02343952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02343952, "Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02343952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*